VERACYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.31 USD | -0.87% |
|
-0.72% | -29.81% |
| Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
| Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,364 | 2,833 | 2,927 | 1,703 | 2,009 | 1,476 | - | - |
| Enterprise Value (EV) 1 | 1,205 | 2,485 | 2,755 | 1,524 | 1,793 | 1,256 | 1,209 | 1,140 |
| P/E ratio | -103 x | -74.2 x | -37.1 x | -46.5 x | -27 x | -80.5 x | -463 x | -1,287 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11.3 x | 24.1 x | 13.3 x | 5.74 x | 5.57 x | 3.71 x | 3.33 x | 3.01 x |
| EV / Revenue | 10 x | 21.2 x | 12.6 x | 5.14 x | 4.97 x | 3.15 x | 2.73 x | 2.32 x |
| EV / EBITDA | -109 x | -90.5 x | -44.2 x | -101 x | -30.6 x | -406 x | 26.4 x | 26.8 x |
| EV / FCF | -201 x | -198 x | -74.5 x | -1,503 x | 52.3 x | 83.2 x | 66.1 x | 36.1 x |
| FCF Yield | -0.5% | -0.5% | -1.34% | -0.07% | 1.91% | 1.2% | 1.51% | 2.77% |
| Price to Book | 5.38 x | 6.76 x | 2.67 x | 1.59 x | 1.93 x | 1.34 x | 1.32 x | 1.3 x |
| Nbr of stocks (in thousands) | 48,840 | 57,897 | 71,043 | 71,753 | 73,040 | 76,448 | - | - |
| Reference price 2 | 27.92 | 48.94 | 41.20 | 23.73 | 27.51 | 19.31 | 19.31 | 19.31 |
| Announcement Date | 2/25/20 | 2/17/21 | 2/28/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 120.4 | 117.5 | 219.5 | 296.5 | 361.1 | 398.3 | 443.4 | 491.2 |
| EBITDA 1 | -11.01 | -27.44 | -62.31 | -15.15 | -58.61 | -3.09 | 45.76 | 42.55 |
| EBIT 1 | -15.13 | -35.39 | -81.9 | -41.08 | -85.8 | -20.1 | -3.519 | 5.978 |
| Operating Margin | -12.57% | -30.12% | -37.31% | -13.85% | -23.76% | -5.05% | -0.79% | 1.22% |
| Earnings before Tax (EBT) 1 | -12.6 | -34.91 | -81.65 | -36.43 | -76.61 | -17 | -2.128 | -10.4 |
| Net income 1 | -12.6 | -34.91 | -75.56 | -36.56 | -74.4 | -17.86 | -3.563 | -1.1 |
| Net margin | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | -4.48% | -0.8% | -0.22% |
| EPS 2 | -0.2700 | -0.6600 | -1.110 | -0.5100 | -1.020 | -0.2400 | -0.0417 | -0.0150 |
| Free Cash Flow 1 | -5.988 | -12.55 | -37 | -1.014 | 34.26 | 15.1 | 18.3 | 31.6 |
| FCF margin | -4.97% | -10.68% | -16.85% | -0.34% | 9.49% | 3.79% | 4.13% | 6.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 39.99% | 74.27% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/17/21 | 2/28/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 60.37 | 67.34 | 67.78 | 72.86 | 75.59 | 80.3 | 82.42 | 90.32 | 90.11 | 98.2 | 93.36 | 98.75 | 101.1 | 105 | 105.6 |
| EBITDA | -10.54 | -5.929 | -8.692 | -4.241 | -3.356 | 1.136 | -3.828 | -1.192 | -24.42 | -29.17 | - | - | - | - | - |
| EBIT 1 | -16.68 | -12.33 | -15.25 | -10.73 | -9.68 | -5.42 | -10.5 | -8.051 | -31.74 | -35.51 | -10.69 | -3.768 | -1.806 | 0.2331 | -1.032 |
| Operating Margin | -27.63% | -18.32% | -22.5% | -14.73% | -12.81% | -6.75% | -12.74% | -8.91% | -35.22% | -36.16% | -11.46% | -3.82% | -1.79% | 0.22% | -0.98% |
| Earnings before Tax (EBT) 1 | -15.48 | -11.32 | -14.46 | -9.647 | -8.875 | -3.441 | -8.091 | -8.277 | -29.77 | -30.47 | -10.68 | -3.755 | -1.792 | 0.2474 | -1.002 |
| Net income 1 | -14.13 | -10.53 | -14.46 | -9.532 | -8.723 | -3.844 | -8.091 | -8.402 | -29.62 | -28.29 | -10.49 | -3.853 | -2.159 | -0.6869 | -1.019 |
| Net margin | -23.4% | -15.64% | -21.33% | -13.08% | -11.54% | -4.79% | -9.82% | -9.3% | -32.87% | -28.81% | -11.24% | -3.9% | -2.14% | -0.65% | -0.96% |
| EPS 2 | -0.2000 | -0.1400 | -0.2000 | -0.1300 | -0.1200 | -0.0500 | -0.1100 | -0.1200 | -0.4100 | -0.3900 | -0.1483 | -0.0600 | -0.0267 | -0.008330 | -0.0275 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/3/22 | 8/2/22 | 11/2/22 | 2/22/23 | 5/4/23 | 8/8/23 | 11/7/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 159 | 349 | 172 | 179 | 216 | 220 | 267 | 336 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.99 | -12.5 | -37 | -1.01 | 34.3 | 15.1 | 18.3 | 31.6 |
| ROE (net income / shareholders' equity) | -7.89% | -10.6% | -9.96% | -3.37% | -7.02% | -2.38% | -1.14% | 0.34% |
| ROA (Net income/ Total Assets) | -6.37% | -9.53% | -9.19% | -3.12% | -6.55% | -2% | -2% | -0.9% |
| Assets 1 | 197.8 | 366.2 | 822.5 | 1,172 | 1,136 | 892.8 | 178.1 | 122.2 |
| Book Value Per Share 2 | 5.190 | 7.240 | 15.40 | 14.90 | 14.30 | 14.40 | 14.60 | 14.90 |
| Cash Flow per Share 2 | -0.1800 | -0.5100 | -0.8200 | -0.1500 | 0.6100 | 0.0700 | 0.1000 | 0.2800 |
| Capex 1 | 2.76 | 2.84 | 5.38 | 8.55 | 9.96 | 12 | 10 | 12 |
| Capex / Sales | 2.29% | 2.41% | 2.45% | 2.88% | 2.76% | 3.01% | 2.26% | 2.44% |
| Announcement Date | 2/25/20 | 2/17/21 | 2/28/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
19.31
USD
Average target price
30.83
USD
Spread / Average Target
+59.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.81% | 1.48B | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M | |
| +13.32% | 332M |
- Stock Market
- Equities
- VCYT Stock
- Financials Veracyte, Inc.
